Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety of Etoposide, Cytarabine, and PEG-rhG-CSF Combination Therapy vs. Disease-Specific Chemotherapy for Hematopoietic Stem Cell Mobilization in Lymphoma
The Affiliated People's Hospital of Ningbo University
99 participants
Aug 1, 2024
INTERVENTIONAL
Conditions
Summary
This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) combination therapy (EAP regimen) in mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma (NHL). A total of 99 NHL patients will be enrolled as research subjects and will be randomly allocated in a 2:1 ratio to compare the EAP regimen versus disease-specific chemotherapy mobilization regimen. The primary endpoint is the proportion of patients achieving the ideal collection value after a single collection (CD34+ cells ≥5×10\^6/kg).
Eligibility
Inclusion Criteria6
- Diagnosed with non-Hodgkin's lymphoma before enrollment.
- Indication for autologous stem cell transplantation (ASCT).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
- Achieved complete remission after multiple courses of chemotherapy.
- Life expectancy ≥ 3 months.
- Subjects must be able to understand the protocol and sign the informed consent.
Exclusion Criteria6
- Cardiac function class II or higher or cardiac ejection fraction \< 40%.
- Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN).
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) more than three times the upper limit of normal (ULN).
- Serum creatinine clearance rate ≤ 50%.
- Patients with active infection.
- History of prior hematopoietic stem cell mobilization.
Interventions
Day 1\~Day 2: 75mg/m\^2
Day 1\~Day 2: 200g/m\^2, q12h
Day 6: 6mg
Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
\[Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) \]± Rituximab (R)
\[Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)\] ± Rituximab
\[High-Dose Methotrexate (MTX) + Cytarabine\] ± Rituximab
\[Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone\] ± Rituximab
\[Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)\] ± Rituximab
\[Gemcitabine + Cisplatin + Dexamethasone + Etoposide\] ± Rituximab
\[Etoposide + Ifosfamide (IFO) + Carboplatin\] ± Rituximab
\[Dexamethasone + Ifosfamide + Ifosfamide + Etoposide\] ± Rituximab
From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06520163